22 septembre 2021 – CYNBIOSE AND HAWKCELL TEAM UP IN A STRATEGIC PARTNERSHIP FOR MRI SERVICES IN PRECLINICAL RESEARCH.
Cynbiose SAS and HawkCell, a young innovative company specialized in MRI (Magnetic Resonance Imaging) for small and large animals, join forces to offer unique services and R&D capabilities for preclinical studies on the non-human primate model. The partnership between Cynbiose and HawkCell will provide both a collaborative R&D offer with biopharmaceutical companies for the development and characterization of physiopathological models. It will also strengthen imaging capabilities for preclinical studies in the translational NHP model.
ACCELERATE PRECLINICAL RESEARCH WITH THE USE OF MRI LEADING TO A CUTTING EDGE AND UNIQUE OFFER.
MRI is a powerful tool for in vivo quantitative analysis of multiple characteristics of living tissues such as inflammation, vascular network, MRI-guided surgery, quantification of CSF, inflammatory parameters and biomarkers for PK and PD studies. Moreover, imaging is the most suitable technic to generate translational endpoints and refinement to procedures while respecting animal welfare and the 3R guidelines
Thanks to Hawkcell’s unique capabilities, Cynbiose aims to leverage these imaging modalities to further support the pre-clinical development of drug candidates and medical devices.
